Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022

This study was supported by postdoctoral fellowship from Tsinghua-Peking Joint Centers for Life Sciences (CLS).PMID:37662522 | PMC:PMC10474375 | DOI:10.1016/j.eclinm.2023.102177

Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Xingxian Luo Xin Du Lin Huang Qixiang Guo Xufeng Lv Cen Wang Haopeng Liu Yue Zhou Xuecai Xue Zhuangqi Li Jingwen Liu Shein-Chung Chow Yue Yang Source Type: research